Compound profile

MOTS-c

The peptide your mitochondria encode, studied for metabolism

What MOTS-c is, how it is thought to switch on AMPK in muscle, the gap between community dosing and validated dosing, what the mostly-preclinical evidence shows, and its 2026 legal status.

Research-grade 10% off with BIOSTACKIQ
How it works

The mechanism

A signal from inside the mitochondria that tells muscle how to handle fuel.

Encoded by mitochondria

Unusually, it is written in the mitochondrial genome, not nuclear DNA. It belongs to a small family of mitochondrial-derived peptides.

Activates AMPK

Under metabolic stress it is proposed to move to the nucleus and, downstream, activate AMPK, the cell's main energy-sensing switch, mainly in muscle.

Better fuel handling

That muscle AMPK activity is the proposed basis for its studied effects on glucose uptake, fat oxidation and insulin sensitivity.

The honest read

Strong in animals, early in humans

The mechanism is well mapped in the lab. The human side is mostly still observational.

What the lab shows

Convincing preclinical

In mice, MOTS-c activated muscle AMPK, improved insulin sensitivity and metabolic health, and acted as an exercise-induced regulator of age-related decline.

Status: consistent and mechanistic

What humans confirm

Still early

Human work is largely observational, like levels falling with age, with controlled efficacy trials early and no completed dose-finding study yet.

Status: promising, not proven

Study by study: MOTS-c human studies.

Evidence

What the research shows

A landmark mouse study, a human-and-mouse exercise study, and trials still in progress.

Mice, metabolism
AMPKinsulin sensitivity improved

The seminal study showed MOTS-c injections activated AMPK in skeletal muscle and improved whole-body insulin sensitivity, including on a high-fat diet.

Lee et al., Cell Metabolism 2015 (PMID 25738459)

Exercise and aging
Exerciseinduced, declines with age

MOTS-c rose with exercise and was tied to age-related physical decline and muscle homeostasis, in both mice and human samples.

Reynolds et al., Nature Communications 2021 (PMID 33473109)

Human efficacy
Pendingno dose trial completed

There is no completed, peer-reviewed human dose-ranging trial. A Phase 2a study was ongoing as of 2026, so efficacy and dosing in people remain open.

Trial status as of 2026

Context: peptides and aging.

Dosing

How it is dosed

This is the honest caveat for MOTS-c: the dosing you see online is convention, not validated science.

Research-community convention
5–10mg per dose

By subcutaneous injection, two to three times weekly, with some protocols using lower daily amounts. Not from a published dose-finding study.

Validated human dose
None established

No completed human dose-ranging trial exists. A Phase 2a study was ongoing as of 2026.

Educational information, not medical advice; dosing should come from a prescriber. Check your math with the dosage calculator.

Safety

Side effects

Human safety data is limited, because controlled human trials are still early.

  • Injection site: pain or redness where it is injected is the main practical effect.
  • Blood sugar: because it acts on glucose handling, low blood sugar is worth watching, especially alongside other glucose-lowering agents.
  • Unknown: long-term human safety is not established given the early stage of trials.
  • Source quality: research-grade material is not tested for identity, purity or sterility.

Caution: if you take insulin or other diabetes medication, a compound studied for insulin sensitivity is a conversation for your doctor first, not a self-experiment.

A fit man in his thirties giving himself a small subcutaneous injection in the abdomen in a bright gym locker room after training
Legal status

MOTS-c's legal status in 2026

Prescription compounding

Under the October 2026 draft HHS policy, licensed 503A pharmacies can compound MOTS-c acetate by injection, by prescription, single-ingredient and fully tested.

Not FDA-approved

The FDA panel voted in favor on July 24, 2026, but it is not on the 503A list yet and is not approved for any medical use. The policy is a draft and nonbinding.

Research versions

MOTS-c sold as a research chemical is for laboratory use only, not for human consumption, and is not covered by the HHS policy.

Updates: FDA peptide status tracker · the 2026 peptide update.

Track it

What to monitor

MOTS-c is one of the few peptides here with real, trackable markers, because its studied effect is metabolic.

  • Fasting glucose and HbA1c at baseline and over time
  • Fasting insulin or a HOMA-IR estimate of insulin sensitivity
  • Body composition and training capacity, logged consistently

The dashboard logs doses and symptoms, and Lab Analysis tracks glucose and insulin markers over time.

A fit woman in her thirties checking fitness and glucose data on her phone at a kitchen table with a healthy breakfast

Frequently asked questions

What is MOTS-c?

MOTS-c is a 16-amino-acid mitochondrial-derived peptide, meaning it is encoded in the mitochondrial genome (in the 12S rRNA region of the MT-RNR1 gene) rather than in nuclear DNA. It is one of a small family of signaling peptides made directly by mitochondria, and it is studied mainly for metabolism, insulin sensitivity and exercise capacity.

How does MOTS-c work?

Under metabolic stress, MOTS-c is proposed to move into the cell nucleus and help regulate stress-response genes, and it has been studied for activating AMPK, a central cellular energy sensor, mainly in skeletal muscle. Because muscle handles most insulin-stimulated glucose disposal, muscle AMPK activation is the proposed basis for its studied effects on glucose uptake, fat oxidation and insulin sensitivity.

Is MOTS-c FDA-approved or legal?

MOTS-c is not FDA-approved for any indication. On July 24, 2026 the FDA's advisory committee voted in favor of adding MOTS-c to the 503A compounding list, and the October 2026 HHS draft policy lets licensed 503A pharmacies compound MOTS-c acetate by injection, by prescription, under strict testing and labeling rules. That is not FDA approval, it is a draft and nonbinding, and it does not cover research-chemical sellers, who market MOTS-c for laboratory use only.

What is the typical MOTS-c dose?

There is no completed, peer-reviewed human dose-ranging trial for MOTS-c, so there is no validated dose. Research-community protocols commonly cite about 5 to 10mg per dose, two to three times weekly, by subcutaneous injection, with some using lower daily amounts. Treat any specific figure as an informal convention, not a clinical dose, until controlled trial data is published. A Phase 2a human trial was ongoing as of 2026.

What does the research actually show?

The strongest efficacy data is still preclinical. A 2015 mouse study found MOTS-c activated AMPK in muscle and improved whole-body insulin sensitivity, and a 2021 study showed MOTS-c is exercise-induced and linked to age-related physical decline in both mice and humans. Human data is mostly observational so far, with controlled efficacy trials still early, so the metabolic claims are promising rather than proven.

Is MOTS-c linked to aging?

Circulating MOTS-c levels have been reported to decline with age in some human studies, which is why it is discussed as a candidate mitochondrial peptide of aging. The 2021 exercise study reinforced that link. That framing is an active area of investigation, not an established clinical fact, so it is best treated as a research hypothesis.

How is MOTS-c different from other metabolic peptides?

Most peptides are encoded in nuclear DNA. MOTS-c is unusual in being encoded by the mitochondria themselves, which is why it is grouped with the mitochondrial-derived peptides rather than with the growth-hormone or incretin peptides. It works through AMPK and muscle metabolism rather than through GH release or the GLP-1 pathway used by drugs like tirzepatide.

Track your protocol

Log doses, glucose, insulin and body composition in one place, and watch the markers that matter. Free.

Sources

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454. PMID 25738459
  2. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12(1):470. PMID 33473109
  3. FDA Pharmacy Compounding Advisory Committee vote, July 24, 2026, and the October 2026 HHS draft 503A peptide compounding policy (MOTS-c acetate, injection). AJMC summary

This content is for informational purposes only and is not medical advice. MOTS-c is not FDA-approved in the United States. A July 2026 FDA advisory vote in its favor is nonbinding, and the October 2026 HHS compounding policy is a draft. No completed human dose-finding trial has been published. Research-grade MOTS-c is sold for laboratory use only, not for human consumption. Always consult a qualified healthcare provider before considering any peptide protocol.